Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

earch, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $10.3 million and $3.6 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

At September 30, 2013, the Company had cash and equivalents of $78.9 million, compared to $17.5 million at December 31, 2012.  The increase of $61.4 million was primarily due to the completion of an initial public offering that raised net proceeds of $58.1 million and to the completion of a concurrent private offering that raised net proceeds of $25.1 million, less cash used to fund operations.

The Company expects its research and development expense to increase as it prepares for the initiation of the Phase 3 clinical trial of quizartinib in relapsed or refractory AML patients, which is expected to begin early in 2014.  Under the base case operating plan, which assumes that the FDA will require a randomized, controlled Phase 3 clinical trial for an NDA submission, the Company currently expects cash and cash equivalents to be sufficient to fund this trial and operations through the receipt of top line data from the Company's Phase 3 trial in approximately 326 relapsed/refractory AML patients. 

Conference Call and Webcast
A conference call hosted by the Ambit management team will be webcast live today at 2pm PT or 5pm ET and can be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. Please specify that you would like to join the "Ambit Third Quarter 2013 Earnings Conference Call" and reference conference ID number 35424048.  If you are unable to listen to the live webcast, a teleconference replay will be available through Thursday,
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 /PRNewswire/ ... en 1974, a été depuis ... compléter les évaluations cliniques traditionnelles par des ... Outcomes) et sur les impacts économiques des ... A cours d,une ...
(Date:9/18/2014)... September 18, 2014 OMICS Group ... globe to participate in the ‘Open Access Week’ ... to OMICS Group Pharma Journals from ... of the fastest emerging Sciences, accelerating with a ... services across the globe. The industry is gearing ...
(Date:9/18/2014)... dysplasia is a group of rare diseases that ... cartilage. Its onset hits at the fetal stage ... in the gene encoding fibroblast growth factor receptor ... of skeletal dysplasia, thanatophoric dysplasia (TD), a skeletal ... and is often lethal, and achondroplasia (ACH), which ...
(Date:9/18/2014)... weight loss and diabetes prevention, could actually hasten the ... do it in a surprising way: by changing the ... substantial population of bacteria residing in our intestines. These ... were published today in Nature . Among other ... Immunology Department, who led this research together with Prof. ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... Elsevier announced today,that its flagship product Scopus, the world,s ... nearly doubling its Arts &,Humanities (A&H) titles. Access to ... April 2009. Currently the Scopus database contains 1,600,titles in ... Many countries will be better represented as ...
... Nov. 24 Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: ... pleased to announce the issuance of its,21st US Patent ... Digitization of the Temporal Point Spread,Function of the Detected ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ) ...
... 24 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ... an agreement with Baxter Oncology GmbH for the,commercial ... is developing picoplatin, its lead product candidate, as ... solid tumors. The Company is,evaluating picoplatin in ...
Cached Biology Technology:Scopus to Expand Arts & Humanities Coverage 2Scopus to Expand Arts & Humanities Coverage 3Imaging Diagnostic Systems is Recognized for Its Advanced Engineering in Time-Resolved Techniques by the US Patent Office 2Imaging Diagnostic Systems is Recognized for Its Advanced Engineering in Time-Resolved Techniques by the US Patent Office 3Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin 2Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin 3
(Date:9/18/2014)... form of camouflage: you don,t just blend in, the ... as uncommon as you might think. Kathryn Feller, from ... the larval life stages of many marine species are ... that most creatures cannot make transparent. Feller explains that ... individual eye unit with an opaque pigment to prevent ...
(Date:9/18/2014)... spend their entire lives nestling in the protective tentacles ... babies they sometimes travel hundreds of kilometres across the ... reef fish has been predicted, this is the first ... distant populations has been observed. , Dr Steve Simpson, ... the University of Exeter, and colleagues from the Australian ...
(Date:9/17/2014)... instrumental in the creation of the Santa Ana Wildfire ... fire threat potential of the powerful, hot, dry Santa ... inferno. The index was introduced Sept. 17 by the ... Diego Gas and Electric. , The index includes four ... be used to help fire agencies and other emergency ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... Science of Food and Agriculture shows that konjac gum ... of E. coli and Salmonella bacteria. The study by ... Centre, the Netherlands, shows that these foodstuffs act as binders ... to the fibrous foods instead of the gut cells of ...
... published online today in the International Journal of Obesity ... of a reduced-calorie diet, helps overweight adults lose more weight ... breakfast of equal calories. [1] This study supports previous ... of Nutrition , which showed that people who ate eggs ...
... Dalton, professor and Georgia Research Alliance Eminent Scholar of ... awarded $9.2 million as part of a major new ... Sciences, part of the National Institutes of Health. ... molecular biology, will address the molecular underpinnings of the ...
Cached Biology News:Adults who eat eggs for breakfast lose 65 percent more weight 2Adults who eat eggs for breakfast lose 65 percent more weight 3UGA researchers win $9.2 million stem cell grant from NIH 2
... Normal;heading 1;heading ... types and experimental ... for standard transfection ... transduction systems. ViraPower ...
... Product Rabbit polyclonal to ... conjugated to KLH, corresponding to amino ... / Specificity Cross-reacts with Rat.Expected to ... Mouse (100% identity with immunogen), Rabbit (100% ...
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Inventory Racks for cryogenic vials. ... cardboard or stainless steel boxes ... cryo vials. Vapor phase ... Platform risers to be ...
Biology Products: